At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Trading 12-11 15:55:20 EST
574.06
+21.59
+3.91%
High589.67Low554.00Vol211.32K
Open554.49D1 Closing552.47Amplitude6.46%
Mkt Cap13.04BTradable Cap6.31BTotal Shares22.71M
T/O120.75MT/O Rate1.92%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Madrigal Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Dow Jones  ·  01:10
Madrigal Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Madrigal Pharmaceuticals Inc : B. Riley Raises Target Price to $670 From $560
THOMSON REUTERS  ·  12-11 21:20
Madrigal Pharmaceuticals Inc : B. Riley Raises Target Price to $670 From $560
B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating
MT Newswires Live  ·  12-11 21:00
B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  12-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Reuters  ·  12-04
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares
Reuters  ·  12-04
Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares
Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!
TIPRANKS  ·  11-22
Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman Reports Disposal of Common Shares
Reuters  ·  11-22
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman Reports Disposal of Common Shares
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  11-22
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra
TIPRANKS  ·  11-22
Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra
Madrigal price target raised to $620 from $568 at H.C. Wainwright
TIPRANKS  ·  11-22
Madrigal price target raised to $620 from $568 at H.C. Wainwright
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  11-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating
MT Newswires Live  ·  11-20
Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating
U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's
Reuters  ·  11-20
U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's
Madrigal Pharmaceuticals Inc : Oppenheimer Raises Target Price to $650 From $600
THOMSON REUTERS  ·  11-20
Madrigal Pharmaceuticals Inc : Oppenheimer Raises Target Price to $650 From $600
Madrigal Pharmaceuticals Is Maintained at Buy by Truist Securities
Dow Jones  ·  11-20
Madrigal Pharmaceuticals Is Maintained at Buy by Truist Securities
Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist
TIPRANKS  ·  11-19
Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist
Madrigal Pharmaceuticals (MDGL) Has a New Rating from Truist Financial
TIPRANKS  ·  11-19
Madrigal Pharmaceuticals (MDGL) Has a New Rating from Truist Financial
Assessing Madrigal Pharmaceuticals After FDA Approval and an 82% Share Price Surge
Simply Wall St.  ·  11-18
Assessing Madrigal Pharmaceuticals After FDA Approval and an 82% Share Price Surge
Madrigal Pharmaceuticals to Join Jefferies Global Healthcare Conference
Reuters  ·  11-17
Madrigal Pharmaceuticals to Join Jefferies Global Healthcare Conference

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--